Cargando…

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance

Despite the initial benefit from treating ERBB2-positive breast cancer with tyrosine kinase inhibitor lapatinib, resistance develops inevitably. Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Hongmei, Du, Liang, Cai, Songwang, Lin, Wan, Chen, Chaoying, Still, Matthew, Yao, Zhimeng, Coppes, Robert P., Pan, Yunlong, Zhang, Dianzheng, Gao, Shegan, Zhang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010868/ https://www.ncbi.nlm.nih.gov/pubmed/35431974 http://dx.doi.org/10.3389/fphar.2022.838171

Ejemplares similares

Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment
por: Yao, Zhimeng, et al.
Publicado: (2023)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
por: Dong, Hongmei, et al.
Publicado: (2022)

Generation and Application of Inducible Chimeric RNA ASTN2-PAPPA(as) Knockin Mouse Model
por: Luo, Yichen, et al.
Publicado: (2022)

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
por: Asbagh, Layka Abbasi, et al.
Publicado: (2014)

Protein tyrosine phosphatase receptor type O (Ptpro) regulates cerebellar formation during zebrafish development through modulating Fgf signaling
por: Liao, Wei-Hao, et al.
Publicado: (2013)

Comprehensively Analyze the Prognosis Significance and Immune Implication of PTPRO in Lung Adenocarcinoma
por: Lin, Zhimin, et al.
Publicado: (2023)

PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis
por: Zhang, Wenjie, et al.
Publicado: (2015)

Retraction for Motiwala et al., Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer
Publicado: (2022)

Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research
por: Hobiger, Kirstin, et al.
Publicado: (2015)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma
por: Gan, Jinfeng, et al.
Publicado: (2020)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression
por: Qi, Leilei, et al.
Publicado: (2017)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
por: Bao, Shengnan, et al.
Publicado: (2020)

Evaluation of the Hypoglycemic Activity of Morchella conica by Targeting Protein Tyrosine Phosphatase 1B
por: Begum, Naeema, et al.
Publicado: (2021)

Protein tyrosine phosphatase receptor type O (PTPRO) knockdown enhances the proliferative, invasive and angiogenic activities of trophoblast cells by suppressing ER resident protein 44 (ERp44) expression in preeclampsia
por: Yang, Yang, et al.
Publicado: (2021)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
por: Raja Sharin, Raja Nur Firzanah Syaza, et al.
Publicado: (2022)

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine
por: Xing, Hua, et al.
Publicado: (2018)

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
por: Oh, Byeongsang, et al.
Publicado: (2014)

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer
por: Hou, Xuben, et al.
Publicado: (2021)

Protein tyrosine phosphatase non-receptor type 2 as the therapeutic target of atherosclerotic diseases: past, present and future
por: Tang, Xiao-Er, et al.
Publicado: (2023)

MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma
por: Yao, Zhimeng, et al.
Publicado: (2019)

Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma
por: Gao, Ying, et al.
Publicado: (2017)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
por: Hong, Yong Sang, et al.
Publicado: (2014)

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells
por: Yallowitz, Alisha, et al.
Publicado: (2018)

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
por: Li, Dun, et al.
Publicado: (2016)

PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism
por: Dai, Weixing, et al.
Publicado: (2022)

CNST is Characteristic of Leukemia Stem Cells and is Associated With Poor Prognosis in AML
por: Liu, Haoyu, et al.
Publicado: (2022)

Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines
por: Wan Mohamad Zain, Wan Nor I′zzah, et al.
Publicado: (2019)

Insight into the Role of the STriatal-Enriched Protein Tyrosine Phosphatase (STEP) in A(2A) Receptor-Mediated Effects in the Central Nervous System
por: Domenici, Maria Rosaria, et al.
Publicado: (2021)

Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations
por: Andreu, Inmaculada, et al.
Publicado: (2020)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis
por: Jia, Ji-Ning, et al.
Publicado: (2020)

Role of ErbB Receptors in Cancer Cell Migration and Invasion
por: Appert-Collin, Aline, et al.
Publicado: (2015)

Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells
por: Xie, Feiling, et al.
Publicado: (2021)

Corrigendum: Neuroprotective Effects of the Anti-Cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis
por: Jia, Ji-Ning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tn2rd6dnp20mujig2qkiad30dk